Tag Archives: Mark Goldsmith

← Older posts

Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they’re “undruggable.” Revolution Medicines is trying to drug the undruggable with small molecules that block the signaling pathways these proteins use to help cancer grow and thrive. With one […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

Warp Drive’s Odyssey Ends with a Buyout—By Revolution, Not Sanofi

Warp Drive Bio started up in 2012 with a potential buyer, Sanofi, already in place. Six years later the Cambridge, MA, company is being acquired—by another startup, Revolution Medicines. The companies aren’t disclosing financial details of the acquisition, other than to say that Warp Drive’s shareholders will be issued Revolution stock. Third Rock Ventures founded […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , | Comments Off on Warp Drive’s Odyssey Ends with a Buyout—By Revolution, Not Sanofi

Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer

Revolution Medicines emerged three years ago to develop drugs from products found in nature and said its lead prospect would be an antifungal compound. Redwood City, CA-based Revolution is now focused on cancer and has raised $56 million to bring a completely different drug into clinical studies. The firm is targeting an enzyme called SHP2, […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer

Third Rock’s New Revolution Looks to Squeeze More Drugs From Nature

Over and over, drugmakers have turned discoveries in nature into human medicine. Aspirin came from the willow plant, and the cholesterol-lowering statins originated in fungi. But once the foundation of the drug business, so-called natural products have fallen out of favor in our high-tech age. Third Rock Ventures thinks it can go back to nature […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , | Comments Off on Third Rock’s New Revolution Looks to Squeeze More Drugs From Nature

“Innovation at Biotech’s Epicenter,” Dec. 17: Check Out the Agenda

A quick reminder that we’re one week away from our annual biotech event in San Francisco. This year, it’s called Xconomy Forum: Innovation at Biotech’s Epicenter, and we’re gathering December 17 in the Mission Bay neighborhood to talk about the emerging science, unique geography, and risk-taking strategies that will spur the Bay Area’s biomedical innovation […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on “Innovation at Biotech’s Epicenter,” Dec. 17: Check Out the Agenda

“Innovation at Biotech’s Epicenter,” Dec. 17: Check Out the Agenda

We’re less than one month away from our annual biotech event in San Francisco. This year, it’s called Xconomy Forum: Innovation at Biotech’s Epicenter, and we’re gathering December 17 in the Mission Bay neighborhood to talk about the emerging science, unique geography, and risk-taking strategies that will spur the Bay Area’s biomedical innovation for the […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on “Innovation at Biotech’s Epicenter,” Dec. 17: Check Out the Agenda

Bay Area Innovators To Shake Up “Biotech’s Epicenter” Event 12/17

We’re one month away from our annual biotech event in San Francisco. This year, it’s called Xconomy Forum: Innovation at Biotech’s Epicenter, and we’re gathering December 17 in the Mission Bay neighborhood to talk about the emerging science, great ideas, and risk-taking strategies that will spur the Bay Area’s biomedical innovation for the next 25 […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bay Area Innovators To Shake Up “Biotech’s Epicenter” Event 12/17

UCSF Chancellor Hawgood Kicks Off “Biotech’s Epicenter” Forum 12/17

It’s my six-month anniversary at Xconomy, and I’m working to put together my first live event. As a native San Franciscan—I believe we’re known as “unicorns,” as folks on the tech side might say—I mulled over the theme and decided, what better way to get people together than to drum up a little hometown pride? […]

Posted in National blog main, San Francisco, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on UCSF Chancellor Hawgood Kicks Off “Biotech’s Epicenter” Forum 12/17

As Expected, Nurix Taps Into $25M for New Drug Discovery

More details have emerged on Nurix, the San Francisco biotech funded by Third Rock Ventures and The Column Group. The two venture firms, which seeded Nurix with $6 million in 2012, announced Thursday they have teamed to provide a $25 million Series B round, which my colleague Bernadette Tansey anticipated last month in this report […]

Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on As Expected, Nurix Taps Into $25M for New Drug Discovery

Two San Francisco Startups Sharing In Third Rock’s Rich Third Fund

Third Rock Ventures, an investment firm known for founding life sciences companies from scratch, made a big splash last year by raising $516 million for its third fund while many of its fellow venture capital firms were struggling. Since then, it’s been putting that new money to work. Over the past three months, Third Rock’s […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Two San Francisco Startups Sharing In Third Rock’s Rich Third Fund← Older posts